Cubist Pharmaceuticals (CBST) 101.94 $CBST Cubist

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cubist Pharmaceuticals (CBST) 101.94 $CBST

Cubist Pharmaceuticals Shares Up 52.7% Since SmarTrend's Buy Recommendation (CBST)
Comtex SmarTrend(R) - Wed Mar 25, 9:59AM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)

52.7% Return Seen to Date on SmarTrend Cubist Pharmaceuticals Call (CBST)
Comtex SmarTrend(R) - Tue Mar 10, 5:08PM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)

Cubist Pharmaceuticals Has Returned 52.7% Since SmarTrend Recommendation (CBST)
Comtex SmarTrend(R) - Mon Feb 09, 11:06AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 4 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)

Uptrend Call Working As Cubist Pharmaceuticals Stock Rises 52.7% (CBST)
Comtex SmarTrend(R) - Mon Feb 02, 9:48AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 3 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)

Merck concludes tender offer to acquire Cubist at USD102.00 per share
M2 - Thu Jan 22, 5:34AM CST
Healthcare company Merck (NYSE:MRK) said on Wednesday that it has acquired all of the outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST) at a purchase price of USD102.00 per share in a tender offer.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 62.90 (+0.11)

Merck Completes Tender Offer to Acquire Cubist
BusinessWire - Wed Jan 21, 7:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 62.90 (+0.11)

Dana Holding Set to Join the S&P MidCap 400
PR Newswire - Tue Jan 20, 4:45PM CST
Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent Merck & Co. Inc. (NYSE: MRK) is acquiring Cubist Pharmaceuticals in a transaction expected to be completed soon, pending final conditions.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 62.90 (+0.11), DAN: 14.48 (+0.06), MHFI: 107.92 (+1.16)

Merck Speeds Up Lung Cancer, HCV Drugs; Filings in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:10PM CST
Merck (MRK) will seek FDA approval for its combination HCV treatment in the first half of this year and clearance to expand the use of Keytruda in lung cancer patients.
CBST: 101.94 (+0.14), MRK: 62.90 (+0.11), BMY: 56.76 (-0.63)

United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 86.98 (-0.05), UTHR: 123.21 (+0.93)

Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 77.42 (-0.96), VNDA: 15.29 (-0.09), IMGN: 2.80 (-0.01), EXEL: 11.35 (+0.20)

Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:00PM CST
Spectrum Pharmaceuticals (SPPI) submitted a new drug application to the FDA for Captisol-enabled melphalan (propylene glycol-free) for the multiple myeloma transplant setting.
CBST: 101.94 (+0.14), LGND: 107.04 (+3.73), SPPI: 5.29 (-0.02), BIOD: 0.42 (-0.01)

Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:10AM CST
Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from a phase III study evaluating its experimental antibiotic, eravacycline.
TTPH: 3.78 (-0.02), JNJ: 119.08 (-0.26), CBST: 101.94 (+0.14), MRK: 62.90 (+0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 53

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 26

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 135

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 32

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 69

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Labcon and Polycarbin Forge Sustainable Partnership for Labs

Updated Category News Views 93

Labcon Teams Up with Polycarbin for Sustainable Solutions Labcon North America, known for its commitment to Earth Friendly® laboratory disposables, is partnering with Polycarbin, a leader in sustainable laboratory solutions. This strategic alliance aims to promote a circular economy within the life sciences and pharmaceutical industries. Joining Forces for Circular...

Continue Reading
Toobit Innovates with New Card Payment for Cryptocurrency Purchases

Updated Category News Views 141

Toobit Introduces Hassle-free Cryptocurrency Purchases Toobit, a leading name in the cryptocurrency market, is breaking new ground by launching a feature that allows users to buy digital currencies using credit and debit cards. This innovative approach is set to simplify the purchasing process, enabling customers to engage in the world of cryptocurrencies with ease and...

Continue Reading
Exploring the UAE's Growing $40.8 Billion Wellness Landscape

Updated Category News Views 222

The UAE's Flourishing Wellness Economy In collaboration with key stakeholders, recent findings indicate that the wellness economy in the UAE has experienced impressive growth of 14.3% from 2019 to 2024. This demonstrates its status as the fastest-growing wellness market in the region. Valuation of the Wellness Sector The value of the wellness industry in the UAE has...

Continue Reading
Waylens Partners with Greater Than for Enhanced Fleet Safety

Updated Category News Views 165

Waylens and Greater Than Join Forces for Fleet Safety In an exciting development for the fleet management industry, Waylens, recognized for its cutting-edge AI video telematics technology, is partnering with Greater Than, a leading provider of risk intelligence focused on road safety and climate impacts. This collaboration aims to enhance fleet safety by integrating video...

Continue Reading
Heavy Options Trading Indicates Optimism for NuScale Power

Updated Category News Views 185

NuScale Power Sees Significant Options Activity Investors are increasingly showing a positive outlook towards NuScale Power (NYSE: SMR), an engagement worth noting in the market landscape. Recent tracking of public options records has revealed notable movements among deep-pocketed investors today. Understanding the Options Landscape Today, the options scanner brought to...

Continue Reading